KOVANAZE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for KOVANAZE (KOVANAZE).
KOVANAZE (norepinephrine and phenylephrine) is a combination of two vasopressors: norepinephrine, an α1-adrenergic receptor agonist with β1-adrenergic activity, and phenylephrine, a selective α1-adrenergic receptor agonist. Both agents cause vasoconstriction and increase blood pressure via activation of α1-adrenergic receptors on vascular smooth muscle.
| Metabolism | Norepinephrine is primarily metabolized by monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT). Phenylephrine is metabolized by monoamine oxidase (MAO) in the liver and gut wall. |
| Excretion | Renal excretion of unchanged drug: ~20-30%; fecal/biliary elimination: minimal (<5%); remainder as metabolites |
| Half-life | Terminal elimination half-life: approximately 7-9 hours following nasal administration; clinical significance: supports twice-daily dosing regimen |
| Protein binding | Approximately 94% bound to serum proteins (mainly albumin and alpha-1-acid glycoprotein) |
| Volume of Distribution | Volume of distribution: approximately 1.5 L/kg; indicates extensive tissue distribution |
| Bioavailability | Intranasal: absolute bioavailability ~10%; oral: negligible due to extensive first-pass metabolism |
| Onset of Action | Intranasal: symptom relief begins within 15-30 minutes; peak effect at 1-2 hours |
| Duration of Action | Duration of action: approximately 12 hours; clinical note: recommended dosing every 12 hours for continued symptom control |
Intravenous bolus of 1 mg/kg over 10 minutes, followed by intravenous infusion of 0.02 mg/kg/min for 4 hours, then 0.01 mg/kg/min for 20 hours.
| Dosage form | SPRAY, METERED |
| Renal impairment | No dose adjustment required for renal impairment. Not removed by hemodialysis. |
| Liver impairment | No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Safety and efficacy not established in severe hepatic impairment (Child-Pugh C). |
| Pediatric use | Safety and efficacy not established in pediatric patients. |
| Geriatric use | No specific dose adjustment recommended, but monitor renal function and QT interval due to increased sensitivity. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for KOVANAZE (KOVANAZE).
| Breastfeeding | Excretion into human milk unknown; M/P ratio not determined. Due to potential adverse effects in infant (irritability, poor feeding), breastfeeding is not recommended during therapy. |
| Teratogenic Risk | KOVANAZE (phendimetrazine) is a sympathomimetic amine; no adequate human studies exist. First trimester: avoid due to potential teratogenicity based on animal studies. Second and third trimesters: may cause fetal tachycardia, hypertension, and intrauterine growth restriction; use only if benefit outweighs risk. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to norepinephrine or phenylephrine.","Severe hypertension (e.g., systolic >180 mmHg).","Use with MAO inhibitors or within 14 days of MAOI therapy (risk of hypertensive crisis).","Use with halogenated anesthetics (e.g., halothane) due to risk of ventricular arrhythmias."]
| Precautions | ["Risk of hypertension and bradycardia due to excessive vasoconstriction.","Use with caution in patients with cardiovascular disease (e.g., ischemia, arrhythmias).","Avoid extravasation; may cause tissue necrosis if infiltrated.","Monitor blood pressure and heart rate continuously during administration.","May cause peripheral and visceral ischemia with prolonged use."] |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal blood pressure, heart rate, weight, and fetal growth via ultrasound; assess for signs of preterm labor or placental insufficiency. Perform fetal heart rate monitoring if maternal symptoms of excessive sympathomimetic stimulation occur. |
| Fertility Effects | No controlled human data; animal studies suggest potential for impaired fertility at high doses. Use in women of childbearing potential should be with effective contraception. |